Aptar Pharma
Industry
- Medical Devices
- Pharmaceuticals
- Drug Delivery
- Controlled Release
- Drug Delivery
- Digital Health
- Disease Management
Latest on Aptar Pharma
With its acquisition of Ireland's Amryt Pharma set to complete shortly after Easter, Chiesi Farmaceutici S.p.A. can expect a healthy rise in revenues for 2023 having just posted a strong set of fi
After abuse-deterrent opioid formulations reached a dead-end, the US Food and Drug Administration again is seeing growth in applications for new products that address the opioid crisis. In addition to
After abuse-deterrent opioid formulations reached a dead-end, the US FDA is again seeing growth in applications for new products that address the opioid crisis, led by not one but two applications for
Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. OrsoBio Splurges With Four Concurrent L